Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Romiplostim N01 (Ruilisheng) in aplastic anemia
ChiCTR2500115698Phase 4Not yet recruiting
- Sponsor
- Hebei Provincial Hospital of Traditional Chinese Medicine
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Hebei Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Hematological response rate (primary, 13 weeks). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2500115698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115698.